Table 1.
Baseline characteristics of patients with COVID-19.
| Variables | Entire cohort (n = 145) | Training cohort (n = 97) | Validation cohort (n = 48) | P value |
| Sex (male, n%) | 70 (48.28%) | 49 (50.52%) | 21 (43.75%) | .44∗ |
| Age (y) | 69.00 (63.00, 78.00) | 69.00 (63.50, 77.50) | 69.50 (62.00, 78.75) | .80‡ |
| Comorbidities | 104 (71.72%) | 72 (74.23%) | 32 (66.67%) | .34∗ |
| Hypertension | 67 (46.21%) | 43 (44.33%) | 24 (50.00%) | .52∗ |
| Diabetes | 27 (18.62%) | 22 (22.68%) | 5 (10.42%) | .07∗ |
| Coronary heart disease | 19 (13.10%) | 14 (14.43%) | 5 (10.42%) | .50∗ |
| Chronic obstructive pulmonary disease | 13 (8.97%) | 10 (10.31%) | 3 (6.15%) | .42∗ |
| Cerebrovascular disease | 12 (8.28%) | 7 (7.22%) | 5 (10.42%) | .51∗ |
| White blood cell count (×109/L) | 7.20 (5.45, 10.50) | 6.73 (5.38, 9.75) | 7.68 (5.80, 12.60) | .09‡ |
| Neutrophil count (×109/L) | 5.46 (3.42, 8.72) | 5.27 (3.30, 8.31) | 5.94 (4.03, 10.33) | .15‡ |
| Lymphocyte count (×109/L) | 0.94 (0.56, 1.36) | 0.89 (0.56, 1.32) | 1.06 (0.54, 1.39) | .29‡ |
| Haemoglobin (g/L) | 115.60 ± 19.96 | 115.04 ± 21.02 | 116.73 ± 17.77 | .63† |
| Platelet count (×109/L) | 205.05 ± 98.65 | 199.43 ± 93.94 | 216.40 ± 107.68 | .33† |
| Albumin (g/L) | 32.52 ± 4.56 | 32.45 ± 4.24 | 32.66 ± 5.19 | .81† |
| Alanine aminotransferase (U/L) | 23.60 (15.21, 45.90) | 21.10 (14.75, 46.75) | 25.95 (17.39, 45.30) | .42‡ |
| Aspartate aminotransferase (U/L) | 24.31 (16.95, 39.02) | 23.80 (16.85, 39.80) | 26.05 (16.87, 39.03) | .71‡ |
| Alkaline phosphatase (U/L) | 76.60 (62.70, 98.50) | 76.20 (64.66, 98.50) | 77.21 (56.65, 99.74) | .59‡ |
| Glutamyl transpeptidase (U/L) | 34.70 (21.20, 58.20) | 34.00 (20.45, 56.70) | 36.25 (25.12, 74.93) | .50‡ |
| Total bilirubin (μmol/L) | 11.20 (8.40, 17.30) | 11.80 (8.55, 18.00) | 10.64 (8.03, 14.43) | .14‡ |
| Urea nitrogen (mmol/L) | 5.24 (3.82, 8.05) | 5.15 (3.86, 7.44) | 6.21 (3.80, 8.92) | .35‡ |
| Creatinine (μmol/L) | 67.60 (54.35, 86.40) | 68.20 (54.87, 87.67) | 64.83 (53.20, 84.68) | .49‡ |
| Lactate dehydrogenase (U/L) | 278.70 (198.95, 414.75) | 293.00 (207.25, 442.94) | 261.50 (170.95, 380.30) | .13‡ |
| Creatine kinase (U/L) | 54.00 (31.20, 89.60) | 51.90 (30.90, 89.60) | 57.45 (31.95, 89.60) | .96‡ |
| C-reactive protein (mg/L) | 29.31 (3.23, 84.15) | 37.43 (3.48, 89.36) | 27.19 (2.58, 78.79) | .76‡ |
| Prothrombin time (s) | 13.70 (12.60, 15.47) | 13.87 (12.60, 15.68) | 13.44 (12.50, 15.45) | .43‡ |
| Activated partial thromboplastin time (s) | 28.29 (26.05, 30.74) | 28.46 (26.22, 30.74) | 28.26 (25.82, 30.93) | .99‡ |
| D-dimer (mg/L) | 1.54 (0.62, 3.36) | 1.54 (0.68, 3.35) | 1.54 (0.56, 3.39) | .64‡ |
| Death (n%) | 57 (39.31%) | 39 (40.21%) | 18 (37.50%) | .75∗ |
COVID-19, corona virus disease 2019. P value was the result of comparison between training set and validation set.
∗
Pearson Chi-Squared test.
†
t test.
‡
Mann–Whitney test.